GlassScriptPhysician profile
Joshua D Fox
NPI 1316309586
$2,844.01
in general payments reported to CMS, 2019-2025
20 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 77% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $251 · 2021: $170 · 2022: $332 · 2023: $183 · 2024: $608 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,714 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.43 |
| Education | $209.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $650.13 | 2022-2025 | Affinity, Cygnus Dual, Via Matrix |
| Abbvie INC. | $419.84 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $320.30 | 2020-2025 | Dupixent |
| Janssen Biotech, INC. | $290.81 | 2020-2025 | Tremfya |
| Genzyme Corporation | $228.91 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $219.72 | 2020-2025 | |
| Merz North America, INC. | $145.45 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $126.28 | 2023-2024 | Sotyktu |
| Revance Therapeutics, INC. | $92.86 | 2025 | Daxxify |
| Arcutis Biotherapeutics, INC. | $75.17 | 2023-2025 | Zoryve |
| Pfizer INC. | $65.64 | 2021-2023 | |
| Lilly USA, LLC | $35.41 | 2021-2023 | Taltz |
| Sun Pharmaceutical Industries INC. | $33.06 | 2022 | |
| Galderma Laboratories, L.P. | $30.65 | 2021-2025 | Nemluvio |
| Organon LLC | $30.23 | 2025 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $28.82 | 2021 | |
| Mimedx Group, INC. | $17.70 | 2025 | |
| Biofrontera INC. | $16.69 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Mission Pharmacal Company | $12.08 | 2021 | |
| Mayne Pharma Commercial LLC | $4.26 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.